Medical Communications
Stand Up To Cancer announces four teams dedicated to increasing diversity in clinical trials
February 9, 2023 Medical Communications
Stand Up To Cancer (SU2C) has announced four teams that will focus on increasing diversity in early phase cancer clinical …
FDA grants RMAT designation for Mesoblast’s chronic low back pain treatment
February 9, 2023 Medical Communications
Mesoblast Ltd, an Australian regenerative medicine company leading in allogeneic cellular medicines for inflammatory diseases, announced that its treatment for …
Scottish biotech aims to cure common cold
February 8, 2023 Medical Communications
Scottish biotech company ScotBio has announced that it has seen “promising initial results” from its attempts to extract a cure …
AstraZeneca’s Forxiga approved in EU for chronic heart failure
February 7, 2023 Medical Communications
AstraZeneca has announced that its drug, Forxiga, has been approved in the EU for the treatment of symptomatic chronic heart …
Genentech shares positive results from global phase 3 trials for crovalimab in PNH
February 7, 2023 Medical Communications
Following the global COMMODORE 2 study, Genentech has announced positive data for crovalimab in treating patients with paroxysmal nocturnal haemoglobinuria …
Boston Scientific fined $42m over patent infringement
February 6, 2023 Medical Communications
A five-year legal battle between Boston Scientific and TissueGen has culminated in a $42m fine, which Boston Scientific must pay …
Drug-resistant bacteria found in eye drops has infected 55 people in 12 states
February 3, 2023 Medical Communications
A strongly drug-resistant bacteria has been found in multiple brands of artificial tears eyedrops; the most commonly reported was EzriCare …
DrugBAN AI expected to reduce costs and speed up drug discovery
February 3, 2023 Medical Communications
In a collaboration between Sheffield University and pharma giant, AstraZeneca, a new AI has been developed which could help deliver …
Genoscience Pharma received Orphan Drug Designation for hepatocellular carcinoma drug
February 3, 2023 Medical Communications
French clinical-stage biotech company Genoscience has received FDA Orphan Drug Designation (ODD) for its lead candidate ezurpimtrostat. OOD qualifies the …
FDA approves Axonics’ neurostimulator
February 1, 2023 Medical Communications
US-based medtech company Axonics have received FDA approval for their fourth-generation, rechargeable sacral neuromodulation system for the treatment of chronic …
Amgen launches Amjevita biosimilar on US market
January 31, 2023 Medical Communications
Amgen’s Amjevita (adalimumab-atto) has just launched on the US market, meaning it becomes the first biosimilar to reference the blockbuster …
Johnson & Johnson subsidiary loses US bankruptcy bid
January 31, 2023 Medical Communications
A US federal appeals court in Philadelphia has denied pharma giant Johnson & Johnson’s (J&J) subsidiary’s bankruptcy petition, which aimed …
Pfizer denies purposely mutating COVID-19 virus
January 30, 2023 Medical Communications
Big Pharma company Pfizer has publicly denied allegations that it is deliberately mutating the COVID-19 virus in order to develop …
FDA suggests individual risk assessments for blood donations to secure US blood supply
January 30, 2023 Medical Communications
The FDA has announced that it is suggesting a change from the time-based deferrals for blood donation to an individual …
Researchers develop test to predict Alzheimer’s disease years before diagnosis
January 30, 2023 Medical Communications
Researchers at King’s College London’s Institute of Psychiatry, Psychology & Neuroscience (IoPPN) have developed a blood test which can potentially …
Latest content
October 26, 2026
